(MENAFNEditorial)
National Reference Laboratory will introduce a series of world-class genetic tests at MEDLAB 2016
National Reference Laboratory part of Mubadala''s network of healthcare providers are introducing several world-class assays in the domain of hereditary genetics and therapeutic oncology available through its partner LabCorp and the members of the LabCorp Specialty Testing Group during MEDLAB 2016 as part of the Arab Health 2016 Exhibition & Congress taking place from 25-28 January at Dubai International Convention & Exhibition Centre.
Over the last few years the region has marked an increased need for specialized healthcare services including oncology and genetics resulting in the rapid development of in vitro diagnostics and personalized medicine. Specialized facilities such as National Reference Laboratory are closely following and supporting the development of the healthcare infrastructure in the country and the region by offering tests used as diagnostic and prognostic tools for monitoring and treating a variety of acquired and hereditary diseases including cancers.
''The advancement in Polymerase Chain Reaction (PCR) techniques combined with the introduction of Next Generation Sequencing (NGS) has led to a noticeable increase of laboratory testing in the domains of genetics pharmacogenetics and oncology. Based on the unique genetic profile of each individual we are able to make medical decisions for the specific patient in order to predict risk of disease as well as failure and/or response to treatment'' said Abdul Hamid Oubeisi CEO of National Reference Laboratory . ''Similarly these new methodologies have lowered the costs and therefore made the tests more accessible. We are pleased that through our partnership with LabCorp USA we are able to provide this type of sophisticated testing to patients in the region''.
Selection of assays to be presented during MEDLAB 2016.
VistaSeq
The VistaSeq Hereditary Cancer Panel provides an assessment of genetic mutations within a panel of 27 genes known to be associated with hereditary cancer syndromes. The information provided is used to determine an increased cancer risk in patients with an associated personal or family history. Mutations in different genes may cause the same type of cancer; conversely one gene may be associated with multiple hereditary cancer syndromes. VistaSeq will give healthcare providers and patients additional information to assist in understanding further monitoring and appropriate medical management options.
IntelliGEN
Integrated Oncology''s IntelliGEN assay provides an assessment of targetable mutations within a panel profile of 50 cancer genes known to be involved in the development progression and/or treatment of cancers. Included in the panel are well-established biomarkers that may direct therapeutic decisions. IntelliGEN may be useful as a tool in multiple clinical settings including when guideline-recommended biomarker evaluation yields no targeted therapeutic option when relapse or disease progression has occurred after prior therapies when the tumor is poorly differentiated and of uncertain origin when the cancer lacks an effective standard-of-care therapy at the time of diagnosis when there is limited tissue to perform guideline-recommended biomarker evaluation or when a broad profile of potential gene targets for future clinical trials would be useful.
BRCAssure
The BRCA1 and BRCA2 (breast cancer 1 and 2) genes are two genes found within everyone''s normal genetic material. When mutations or gene alterations are found within these genes the mutations can cause an increased risk for several specific types of cancer. The BRCA mutations can be passed down through a family and are associated with hereditary breast cancer and ovarian cancer. Genetic testing for BRCA1 and BRCA2 mutations is available for those individuals at increased risk and can help provide information about the risk for developing breast cancer ovarian or other cancers.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.